



**THOMSON MEDICAL GROUP LIMITED**  
(Incorporated in the Republic of Singapore)  
(Company Registration No. 199908381D)

---

**THOMSON MEDICAL GROUP LIMITED ISSUES S\$155,000,000 5.25% NOTES DUE 2027  
PURSUANT TO THE S\$1,000,000,000 MULTICURRENCY DEBT ISSUANCE PROGRAMME OF  
THOMSON MEDICAL GROUP LIMITED**

---

Further to the announcements by Thomson Medical Group Limited (the "**Company**") on 6 May 2024 and 7 May 2024, the board of directors (the "**Board**") of the Company wishes to announce that it has issued S\$155,000,000 in aggregate principal amount of 5.25% notes due 2027 (the "**Series 004 Notes**"). The Series 004 Notes were issued pursuant to the S\$1,000,000,000 Multicurrency Debt Issuance Programme established by the Company on 28 June 2019 and updated on 21 April 2023 (the "**Programme**"). DBS Bank Ltd. has been appointed as the sole global coordinator and DBS Bank Ltd., Maybank Securities Pte. Ltd., Oversea-Chinese Banking Corporation Limited, UBS AG Singapore Branch and United Overseas Bank Limited have been appointed as the joint lead managers and joint bookrunners in relation to the Series 004 Notes.

Approval in-principle has been received from the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") for the listing and quotation of the Series 004 Notes on the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 004 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Company, its subsidiaries, its associated companies (if any), the Programme or the Series 004 Notes.

The Series 004 Notes are expected to be listed on the SGX-ST on 14 May 2024.

**By Order of the Board**

**THOMSON MEDICAL GROUP LIMITED**

**Wilson Sam**

Executive Director and Group Chief Financial Officer

13 May 2024